Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | IGFBP5 | P24593 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221819 | 0.91 | GRM2 (0.42) | GRM2ADORA2AADORA1LOXLOXL2 | |
| SCHEMBL2224850 | 0.85 | GRM2 (0.46) | GRM2IGFBP5ADORA2AIGFBP3ALOX15 | |
| SCHEMBL12958877 | 0.85 | ALOX15 (0.53) | GRM2IGFBP5LOXLOXL2IGFBP3 | |
| SCHEMBL6888507 | 0.82 | ADORA2A (0.39) | GRM2IGFBP5ADORA2AADORA1 | |
| SCHEMBL17296541 | 0.81 | CHRM1 (0.50) | — | |
| SCHEMBL17583090 | 0.80 | GRM2 (0.46) | GRM2ADORA2AADORA1ALOX15DHODH | |
| SCHEMBL27886352 | 0.79 | LOX (0.36) | GRM2ADORA2AADORA1LOXLOXL2 | |
| SCHEMBL6891498 | 0.78 | CHRM1 (0.50) | — | |
| SCHEMBL30744928 | 0.75 | GRM2 (0.43) | GRM2IGFBP5ADORA2AADORA1IGFBP3 | |
| SCHEMBL2225368 | 0.74 | GRM2 (0.43) | GRM2ALOX15PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512243-B1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2512243-B1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| CN-102651970-A | Quinoline amide m1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2012-08-29 | — | — | CN | disclosed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | GRM2 123/4885IGFBP5 3995/4885ADORA2A 48/4885 |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | GRM2 124/4885IGFBP5 4146/4885ADORA2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.